Amedisys Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Mizuho Securities Upgrades Amedisys (AMED) to Buy; Pay Up for Strong Management
May 3, 2017 7:30 AM EDTMizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $65.00.
Analyst Sheryl Skolnick is positive on management amid Q1 results. "AMED's 1Q17 result demonstrates just that: not only are cost savings real, but the balanced approach to... More
